Standard Bariatrics, Inc.

Standard Bariatrics, Inc. is a U. S. -based company specializing in advanced medical devices for bariatric surgery, focusing on innovative stapling technology to enhance surgical outcomes.

Founded in 2014 and headquartered in Cincinnati, US, Standard Bariatrics, Inc. develops advanced solutions for bariatric surgery. In August 2022, they were acquired by Teleflex Inc. from River Cities Capital for USD 170 mn in cash, with potential additional payments based on milestones.

The company has completed a total of 6 deals since its inception, with its latest funding round being a Trade Sale in 2022, bringing the total amount raised to USD 170 mn. The CEO of the company is Matt Sokany. Standard Bariatrics specializes in advanced medical devices for bariatric surgery, primarily focusing on their flagship product, the Titan SGS™ Stapler, which is designed for sleeve gastrectomy procedures. This stapler features a unique mechanism that delivers a continuous staple line in one firing, aimed at reducing postoperative complications and ensuring consistent surgical anatomy.

Additional products include the Standard Clamp®, which assists in staple line planning, and the Standard Precision Bougie™ Device for anatomical alignment, serving bariatric surgeons across North America and select international markets. Operating on a business-to-business model, Standard Bariatrics generates revenue through direct sales of its medical devices, including the Titan SGS™ Stapler, Standard Clamp®, and Standard Precision Bougie™ Device, to healthcare providers and surgical facilities. The company engages in partnerships with group purchasing organizations to broaden access to their products, enabling bulk orders within the specialized field of bariatric surgery. Following the acquisition by Teleflex Inc.

, Standard Bariatrics is expected to leverage its resources for future growth. The company is focused on launching additional innovative products and expanding its market presence. Specific goals include targeting new geographic regions for market entry by early 2023 and utilizing the recent USD 170 mn funding to enhance research and development for upcoming devices. The acquisition is subject to regulatory approvals and is anticipated to be finalized by early Q4 2022.